# Corticosteroids Market

> Corticosteroids Market Research Report: Size, Share, Trend Analysis By Types (Systemic Corticosteroids, Topical Corticosteroids, Inhaled Corticosteroids, Nasal Corticosteroids, Ophthalmic Corticosteroids), By Applications (Allergic Disorders, Dermatological Disorders, Respiratory Disorders, Autoimmune Disorders, Oncological Disorders), By Route of Administration (Oral, Injection, Topical, Inhalation, Nasal), By End Use (Hospitals, Clinics, Homecare, Pharmaceutical Companies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 2.41%
- **2024:** $ 57.7 Billion
- **2025:** $ 59.09 Billion
- **2035:** $ 74.98 Billion
- **Key Players:** Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), GlaxoSmithKline (GB), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Mylan (US)

**Report ID:** MRFR/HC/41475-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/corticosteroids-market-43141

---

## Market Summary

## **Corticosteroids Market Overview**

Corticosteroids Market Size was estimated at 56.34 (USD Billion) in 2023. The Corticosteroids Market Industry is expected to grow from 57.7(USD Billion) in 2024 to 75.0 (USD Billion) by 2035. The Corticosteroids Market CAGR (growth rate) is expected to be around 2.41% during the forecast period (2025 - 2035).

## **Key Corticosteroids Market Trends Highlighted**

The Global Corticosteroids Market is witnessing significant growth driven by several key market drivers. The increasing prevalence of chronic diseases such as asthma, allergies, and autoimmune disorders has led to a higher demand for corticosteroid medications. Additionally, the rising awareness among healthcare professionals and patients about the efficacy of corticosteroids in managing various conditions contributes to market expansion. 

Advances in drug formulation and delivery methods enhance the effectiveness and tolerability of these medications, further boosting their adoption. Increased investment in research and development is also propelling innovations in corticosteroid therapies, catering to unmet medical needs and improving patient outcomes.There are ample opportunities to be explored within the corticosteroids landscape. The growing population base, especially in emerging markets, presents a considerable scope for market penetration. Emerging economies are experiencing a rise in healthcare expenditure and improved access to medications, creating a favorable environment for corticosteroid products. 

Furthermore, the aging population globally is increasingly susceptible to chronic conditions, which can lead to heightened demand for corticosteroid treatments. Collaborations between pharmaceutical companies and research institutions can also foster innovative discoveries, allowing for the introduction of new therapies that address current limitations.Recent trends in the corticosteroids market highlight a shift towards personalized medicine, with a focus on tailoring treatments to individual patient needs. There is also an increasing interest in biological therapies and alternative treatment options, which may impact the market dynamics of traditional corticosteroids. 

Moreover, the ongoing digital transformation in healthcare is enabling better patient engagement, adherence to treatment regimens, and telemedicine solutions for monitoring patients, thus influencing corticosteroid treatment approaches. Overall, the interplay of these factors shapes the current landscape of the Global Corticosteroids Market, presenting both challenges and avenues for growth and innovation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Corticosteroids Market Drivers**

### Growing Prevalence of Chronic Diseases

The Global Corticosteroids Market is primarily boosted by factors like an increase in the global population suffering from ailments like asthma, rheumatoid arthritis and inflammatory bowel disease. These diseases tend to be chronic and require long-term management, which involves the use of corticoids. With people growing old, the number of patients complaining about chronic diseases is increasing, and thus, the demand for corticosteroids is increasing.

Advancements in the medical world, along with more and more people becoming aware of the plethora of options available for the treatment of various diseases, have resulted in both doctors and patients taking up corticosteroid therapies more often. With an improving global economy, there is already an increase in the number of people in these regions that have access to better healthcare facilities and medicine which means the usage of corticosteroids will be on the rise amongst these populations.

There are new methods being discovered for the effective use of corticosteroids and this utilization leads to more research and development. So, the increase in patients suffering from chronic diseases provides a good basis for the constantly increasing incidence of corticosteroid use and allows the Global Corticosteroids Market to be positively valued for years to come.

### Increased Research and Development Activities

The Global Corticosteroids Market Industry is witnessing a surge in research and development activities aimed at improving existing corticosteroid formulations and exploring new therapeutic applications. Pharmaceutical companies are investing significantly in R&D to design novel drug delivery systems, enhance efficacy, and reduce potential side effects associated with corticosteroid use. Innovations such as biologics combined with corticosteroids for more targeted treatments are gaining traction, which could lead to new opportunities in the market.This focus on R is vital as it not only caters to evolving patient needs but also enhances the competitive landscape within the Global Corticosteroids Market.

### Growing Awareness of Treatment Options

As healthcare awareness increases globally, patients are becoming more informed about their treatment options, including the benefits and applications of corticosteroids. With the rise of health information available through digital platforms, patients are seeking specific medications for their conditions, notably corticosteroids. This growing awareness encourages patients to discuss treatment plans with healthcare professionals, increasing the potential for corticosteroid prescriptions.Additionally, educational initiatives from organizations and health systems play a crucial role in informing both patients and healthcare practitioners about the developments in corticosteroid therapies, thereby driving the growth of the Global Corticosteroids Market.

## **Corticosteroids Market Segment Insights**

### **Corticosteroids Market Type Insights**

The Global Corticosteroids Market has witnessed notable growth and diversification across its various types, with a projected market value of 57.7 USD Billion in 2024, escalating to 75.0 USD Billion by 2035. Among the different categories, Systemic Corticosteroids stand out with a valuation of 21.5 USD Billion in 2024, which is significant as it caters to a wide range of inflammatory and autoimmune conditions, thereby dominating a substantial portion of the market. Following closely, [Topical Corticosteroids](../../../reports/topical-corticosteroids-market-4331) are valued at 15.0 USD Billion in 2024, reflecting their crucial role in addressing skin disorders and conditions like eczema and psoriasis.

This segment is well-regarded due to its direct application in affected areas, offering patients convenient and effective relief. Inhaled Corticosteroids, valued at 10.5 USD Billion in 2024, play a critical role in the management of asthma and chronic obstructive pulmonary disease (COPD), delivering localized treatment with minimal systemic exposure, which enhances patient compliance and treatment outcomes. Concurrently, Nasal Corticosteroids, worth 6.0 USD Billion in 2024, are vital in managing allergic rhinitis and sinusitis, providing effective anti-inflammatory benefits that enhance the quality of life for millions suffering from nasal allergies.

Lastly, the Ophthalmic Corticosteroids segment, valued at 5.7 USD Billion in 2024, is significant for addressing various ocular conditions, including inflammation and allergies, showcasing the breadth of applications for corticosteroids within the healthcare landscape. The growth determinants for the Global Corticosteroids Market include an increasing prevalence of chronic diseases, a rising geriatric population, and enhanced healthcare awareness. 

However, challenges such as potential side effects and regulatory scrutiny may affect market growth.Nevertheless, there remain vast opportunities for innovation and expansion within the corticosteroids landscape, driven by growing research into better formulations and alternative delivery methods that could significantly enhance efficacy and patient comfort. The segmentation of the Global Corticosteroids Market reflects the extensive application and necessity of these medications in treating a wide array of health issues, thereby paving the way for continued market dominance and growth in the coming years.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Corticosteroids Market Application Insights**

The Global Corticosteroids Market is expected to reach a value of 57.7 USD Billion by 2024, reflecting a steady growth trajectory. Within the Application segment, various conditions such as Allergic Disorders, Dermatological Disorders, Respiratory Disorders, Autoimmune Disorders, and Oncological Disorders play pivotal roles. Allergic Disorders, driven by rising prevalence, maintain significant demand for corticosteroids due to their effectiveness in managing symptoms. 

Dermatological Disorders also dominate, as corticosteroids are commonly prescribed for skin-related issues, benefiting from a growing focus on skincare.The respiratory domain, particularly asthma and chronic obstructive pulmonary disease, remains crucial due to increasing incidences of respiratory ailments globally. Autoimmune Disorders continue to present a substantial market opportunity, as corticosteroids are key in managing inflammation and immune responses. 

Oncological Disorders, while a smaller sector, are gaining traction as corticosteroids are essential in treatment regimens for certain cancers, thereby supporting the overall market growth. Collectively, these Applications reflect the versatility and essential role of corticosteroids in modern therapeutic regimes, making a significant contribution to the Global Corticosteroids Market revenue and its expansion potential in the coming years.

### **Corticosteroids Market Route of Administration Insights**

The Global Corticosteroids Market, valued at 57.7 billion USD in 2024, showcases a diversified approach in its Route of Administration segment. This segment plays a crucial role in determining how corticosteroids are delivered to the patients, influencing both efficacy and patient compliance. The market encompasses various methods, including Oral, Injection, Topical, Inhalation, and Nasal routes, each addressing specific therapeutic needs and conditions. Oral administration remains a common choice due to its convenience and ease of use, while Injection offers rapid relief and is often preferred for acute conditions.Topical applications directly target skin-related issues, making them significant in dermatology.

 Inhalation and Nasal routes are integral for respiratory conditions, allowing for localized treatment and minimizing systemic side effects. The diverse options within the Route of Administration enhance the Global Corticosteroids Market segmentation, catering to a wide range of patient preferences and therapeutic requirements, ultimately driving market growth through improved health outcomes and patient satisfaction. Market trends indicate a continuous adaptation to newer administration methods, reflecting the industry's response to evolving healthcare needs and advancements in drug delivery technologies.

### **Corticosteroids Market End Use Insights**

The Global Corticosteroids Market revenue is poised for significant growth in various End Use areas, with the overall market expected to be valued at 57.7 billion USD by 2024. The demand in hospitals remains strong, as they are critical in administering corticosteroids for various conditions, ensuring patients receive the necessary care. Clinics also play a pivotal role by providing outpatient treatments, contributing to the accessibility of these medications. Homecare services are becoming increasingly important, especially for chronic patients who require ongoing corticosteroid therapy, presenting a growing opportunity in this segment.

Pharmaceutical companies are essential as they manufacture and innovate corticosteroid products, addressing diverse therapeutic needs. The Global Corticosteroids Market data indicates that the industry is driven by rising incidences of allergic conditions and autoimmune diseases while also facing challenges related to regulatory scrutiny and side effects. Nonetheless, ongoing advancements in drug formulations and delivery methods present opportunities for market growth and expansion across these varied end-use channels. With a notable emphasis on hospitals and homecare services, these sectors are expected to dominate due to their integral role in patient management and treatment adherence.

### **Corticosteroids Market Regional Insights**

The Corticosteroids Market shows significant regional variation, with North America leading the way. In 2024, North America is valued at 24.0 USD Billion, expected to rise to 30.0 USD Billion by 2035, highlighting its majority holding in the market due to advanced healthcare infrastructure and high demand for corticosteroid treatments. Europe follows as the second-largest market with a value of 15.5 USD Billion in 2024, increasing to 19.5 USD Billion in 2035, driven by the rising prevalence of autoimmune diseases. 

The APAC region, valued at 10.0 USD Billion in 2024 and projected to reach 12.5 USD Billion by 2035, is gaining traction as a growing market due to expanding healthcare facilities and increasing patient awareness.South America, with a market value of 4.2 USD Billion in 2024, is expected to grow to 5.2 USD Billion by 2035, presenting opportunities driven by enhancements in healthcare access. Meanwhile, the MEA region, though smaller at 4.0 USD Billion in 2024, is projected to increase to 5.8 USD Billion, showing potential as industries develop.

This regional segmentation reflects diverse market dynamics and varying growth drivers inherent in the Global Corticosteroids Market revenue landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Corticosteroids Market Key Players and Competitive Insights:**

The Global Corticosteroids Market is characterized by a dynamic competitive landscape driven by various factors, including advancements in pharmaceutical technologies, increasing incidences of chronic diseases, and the growing acceptance of corticosteroid products in treating a wide range of health conditions such as autoimmune disorders, asthma, and allergies. The market includes a plethora of players ranging from established pharmaceutical giants to emerging biotech firms, each vying for market share through innovative drug formulations, strategic partnerships, and robust marketing strategies. 

Furthermore, regulatory approvals and clinical trial results heavily influence market dynamics, compelling companies to continuously invest in research and development to stay ahead in the competitive race. As the market evolves, trends such as personalized medicine and the development of combination therapies are expected to appear, creating new opportunities and challenges within the space.Roche holds a prominent position in the Global Corticosteroids Market due to its strong portfolio of products and commitment to innovation. The company leverages its extensive research capabilities to develop corticosteroid medications that address critical patient needs across multiple therapeutic areas.

Roche's strength lies in its established reputation for quality and efficacy, which enhances consumer trust and loyalty. 

Furthermore, strategic collaborations and partnerships allow Roche to enhance its market presence and expand its distribution channels. With a focus on patient-centric solutions, the company’s approach encompasses not only the pharmacological aspects of corticosteroids but also emphasizes education and support services for healthcare providers and patients alike. This holistic strategy positions Roche as a leader in the corticosteroid segment, ensuring both sustainability and growth in a competitive marketplace.Amgen, known primarily for its focus on innovative biologics, also plays a significant role in the Global Corticosteroids Market.

The company's integration of advanced biotechnological methods into corticosteroid production enhances the therapeutic impact and safety profiles of its offerings. 

Amgen’s commitment to research in chronic and inflammatory diseases positions it uniquely to capitalize on the increasing demand for effective corticosteroid treatments. The company has made substantial investments in clinical trials and RD initiatives to explore novel applications and formulations of corticosteroids, aligning its objectives with contemporary healthcare needs. In addition, Amgen's significant presence in emerging markets allows it to tap into new customer bases, thereby strengthening its competitive stance. By maintaining a focus on scientific innovation and leveraging its extensive experience in biologics, Amgen is positioned to redefine the landscape of the corticosteroid market in the years to come.

**Key Companies in the Corticosteroids Market Include:**

- Roche
- Amgen
- Johnson and Johnson
- Merck and Co
- Pfizer
- Teva Pharmaceutical Industries
- GlaxoSmithKline
- Bristol Myers Squibb
- AbbVie
- Eli Lilly and Company
- Sanofi
- Mylan N.V.
- Novartis
- AstraZeneca
- **[Gilead Sciences](https://www.gilead.com/medicines)**

### Corticosteroids Market Industry Developments

- **Q2 2024: FDA approves Hikma Pharmaceuticals’ generic version of Flovent HFA inhaler** Hikma Pharmaceuticals received FDA approval for its generic fluticasone propionate HFA inhalation aerosol, a corticosteroid used for asthma, marking a significant addition to the U.S. generic inhaler market.
- **Q1 2024: AstraZeneca receives EU approval for Airsupra, a fixed-dose combination including inhaled corticosteroid** AstraZeneca announced European Commission approval for Airsupra, a fixed-dose combination of albuterol and budesonide, expanding its respiratory portfolio in the corticosteroids segment.
- **Q2 2024: GSK launches Trelegy Ellipta in Japan for COPD and asthma** GlaxoSmithKline launched Trelegy Ellipta, a triple therapy inhaler containing an inhaled corticosteroid, in Japan following regulatory approval for use in both COPD and asthma patients.
- **Q1 2024: Sun Pharma receives US FDA approval for generic prednisolone oral solution** Sun Pharmaceutical Industries received US FDA approval to market its generic prednisolone oral solution, a corticosteroid used to treat various inflammatory and autoimmune conditions.
- **Q2 2024: Pfizer completes acquisition of Arena Pharmaceuticals, expanding immuno-inflammatory pipeline** Pfizer finalized its acquisition of Arena Pharmaceuticals, gaining access to a pipeline of immuno-inflammatory drugs, including corticosteroid-based therapies.
- **Q3 2024: Sanofi opens new manufacturing facility for corticosteroid inhalers in France** Sanofi inaugurated a new production facility in France dedicated to manufacturing inhaled corticosteroid products, aiming to meet growing European demand.
- **Q2 2024: Teva and Alvotech announce FDA acceptance of BLA for AVT04, a biosimilar to Stelara with corticosteroid-sparing potential** Teva and Alvotech reported that the FDA accepted their Biologics License Application for AVT04, a biosimilar to Stelara, which is used in combination with corticosteroids for certain autoimmune diseases.
- **Q1 2024: Novartis launches Enerzair Breezhaler in Canada, a triple therapy including inhaled corticosteroid** Novartis launched Enerzair Breezhaler, a triple combination inhaler containing an inhaled corticosteroid, in the Canadian market for asthma management.
- **Q2 2024: FDA approves Lupin’s generic budesonide inhalation suspension** Lupin received FDA approval for its generic budesonide inhalation suspension, a corticosteroid used in the treatment of asthma in pediatric patients.
- **Q3 2024: Cipla receives UK MHRA approval for Fluticasone Propionate nasal spray** Cipla received regulatory approval from the UK MHRA for its Fluticasone Propionate nasal spray, expanding its corticosteroid product offerings in Europe.
- **Q2 2024: Astellas Pharma announces partnership with Catalent for corticosteroid inhaler development** Astellas Pharma entered a partnership with Catalent to develop and manufacture a new inhaled corticosteroid therapy targeting respiratory diseases.
- **Q1 2025: Glenmark Pharmaceuticals receives US FDA approval for generic mometasone furoate nasal spray** Glenmark Pharmaceuticals received US FDA approval to market its generic mometasone furoate nasal spray, a corticosteroid indicated for allergic rhinitis.

## **Corticosteroids Market Segmentation Insights**

### **Corticosteroids Market** **Type** **Outlook**

- Systemic Corticosteroids
- Topical Corticosteroids
- Inhaled Corticosteroids
- Nasal Corticosteroids
- Ophthalmic Corticosteroids

### **Corticosteroids Market** **Application** **Outlook**

- Allergic Disorders
- Dermatological Disorders
- Respiratory Disorders
- Autoimmune Disorders
- Oncological Disorders

### **Corticosteroids Market** **Route of Administration** **Outlook**

- Oral
- Injection
- Topical
- Inhalation
- Nasal

### **Corticosteroids Market** **End Use** **Outlook**

- Hospitals
- Clinics
- Homecare
- Pharmaceutical Companies

### **Corticosteroids Market** **Regional** **Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Rising Geriatric Population

The aging population is a significant factor contributing to the growth of the Corticosteroids Market. Older adults are more susceptible to chronic diseases that require corticosteroid treatment, such as arthritis and respiratory disorders. As the geriatric demographic continues to expand, the demand for corticosteroids is expected to increase correspondingly. This demographic shift presents both challenges and opportunities for the market, as healthcare systems must adapt to meet the needs of an aging population. Consequently, the corticosteroid market is poised for growth, driven by the necessity to manage age-related health issues effectively.

### Growing Awareness and Education

There is a notable increase in awareness and education regarding the benefits and risks associated with corticosteroid use, which is positively impacting the Corticosteroids Market. Healthcare professionals and patients are becoming more informed about the therapeutic advantages of corticosteroids in managing various conditions. This heightened awareness is leading to more prescriptions and a broader acceptance of corticosteroid therapies. Furthermore, educational initiatives aimed at demystifying corticosteroid use are likely to foster a more favorable perception, thus driving market growth. As patients become more proactive in managing their health, the demand for corticosteroids is expected to rise.

### Regulatory Support and Approvals

Regulatory bodies are increasingly providing support for the development and approval of corticosteroid medications, which is a crucial driver for the Corticosteroids Market. Streamlined approval processes and favorable regulatory frameworks encourage pharmaceutical companies to invest in corticosteroid research and development. This regulatory environment not only facilitates the introduction of new corticosteroid products but also enhances market competition. As a result, patients gain access to a wider array of treatment options, which can lead to increased market penetration. The ongoing collaboration between regulatory agencies and the pharmaceutical industry is likely to sustain this positive trend.

### Advancements in Drug Formulations

Innovations in drug formulations are significantly influencing the Corticosteroids Market. The development of novel delivery systems, such as inhalers and transdermal patches, enhances the efficacy and patient compliance of corticosteroid therapies. These advancements not only improve the therapeutic outcomes but also expand the range of applications for corticosteroids. For instance, the introduction of long-acting formulations has been shown to provide sustained relief for chronic conditions, thereby increasing their market share. As pharmaceutical companies continue to invest in research and development, the market is likely to witness a surge in new corticosteroid products.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as asthma, rheumatoid arthritis, and inflammatory bowel disease is a primary driver of the Corticosteroids Market. As these conditions become more prevalent, the demand for effective treatment options escalates. Corticosteroids Market are often prescribed to manage inflammation and suppress the immune response, making them a cornerstone in the therapeutic arsenal against these ailments. According to recent estimates, the prevalence of asthma alone affects millions, leading to a substantial market for corticosteroid medications. This trend indicates a growing reliance on corticosteroids, thereby propelling the market forward.

## Future Outlook

The Corticosteroids Market is projected to grow at a 2.41% CAGR from 2025 to 2035, driven by increasing prevalence of chronic diseases and advancements in drug formulations.

**New opportunities:**

- Development of biosimilar corticosteroids to enhance market access.
- Expansion into emerging markets with tailored corticosteroid therapies.
- Investment in digital health platforms for corticosteroid management solutions.

By 2035, the Corticosteroids Market is expected to solidify its position as a vital segment in global healthcare.

## Segment Insights

### By Type: Systemic Corticosteroids (Largest) vs. Inhaled Corticosteroids (Fastest-Growing)

In the Corticosteroids Market, Systemic Corticosteroids hold a significant share, making them the largest segment due to their extensive use in treating various autoimmune diseases and inflammatory conditions. Following closely, Topical and Inhaled Corticosteroids also play crucial roles with notable shares, especially in dermatological and respiratory conditions, respectively. Nasal and Ophthalmic Corticosteroids cater to specialized areas, addressing specific health needs effectively, but they represent smaller portions of the overall market.

Corticosteroid Types: Systemic (Dominant) vs. Inhaled (Emerging)

Systemic Corticosteroids are critical in managing severe inflammatory and immune disorders, making them the dominant choice in the market. Their wide-ranging applications in chronic diseases ensure they maintain a strong market position. In contrast, Inhaled Corticosteroids are emerging rapidly, particularly in the management of asthma and other respiratory conditions. Their growth is driven by increasing asthma prevalence and rising awareness about respiratory health. The formulation advancements and aerosol delivery methods enhance patient compliance, propelling the segment's expansion, as patients increasingly prefer targeted therapy options.

### By Application: Allergic Disorders (Largest) vs. Autoimmune Disorders (Fastest-Growing)

In the Corticosteroids Market, Allergic Disorders hold the largest share among the various applications, largely due to the increasing prevalence of allergies and the growing awareness of effective treatment options. This segment encompasses conditions such as [allergic rhinitis](https://www.marketresearchfuture.com/reports/allergic-rhinitis-market-1547), asthma, and food allergies, which collectively contribute significantly to the demand for corticosteroid therapies. Following closely, Autoimmune Disorders have emerged as a fast-growing segment, driven by the rising incidence of autoimmune diseases such as rheumatoid arthritis and lupus, which require potent anti-inflammatory treatments to manage symptoms effectively. Over recent years, the growth trends in the market have been significantly influenced by advancements in corticosteroid formulations and delivery methods, such as inhalers and topical applications. The increasing focus on personalized medicine and improved healthcare access is further propelling the adoption of corticosteroids for treating a variety of conditions. Additionally, the ongoing research into new corticosteroid compounds aimed at reducing side effects is likely to stimulate growth in both the Allergic and Autoimmune Disorder segments, enhancing patient outcomes and satisfaction.

Allergic Disorders (Dominant) vs. Oncological Disorders (Emerging)

The Allergic Disorders segment remains dominant in the Corticosteroids Market, characterized by its well-established treatment protocols and a broad range of corticosteroid options available for managing allergic reactions. This segment thrives due to its adaptability in treating various allergic conditions, benefiting from extensive clinical research and a robust distribution network. In contrast, the Oncological Disorders segment is considered emerging, spurred by an increasing focus on the role of corticosteroids in managing cancer-related symptoms, particularly within chemotherapy regimens. Despite its smaller market share, the growing recognition of corticosteroids' utility in alleviating treatment-related side effects, such as nausea and inflammation, positions this segment for significant growth in the coming years.

### By Route of Administration: Oral (Largest) vs. Injection (Fastest-Growing)

The corticosteroids market shows a diverse distribution among various routes of administration, with oral corticosteroids holding the largest share. This preference stems from their convenience and ease of use for patients, often leading to higher adherence to treatment. In contrast, the injection route has gained momentum as patients and healthcare providers recognize its efficacy in delivering higher doses directly into the system, reflecting a growing interest in parenteral therapies. The growth trends in this segment are significantly influenced by advancements in drug formulations and administration techniques. Innovations in injectable corticosteroids, for instance, have made them more appealing due to their rapid action and long-lasting effects. Furthermore, the rising incidence of chronic conditions and inflammatory diseases globally drives demand for effective treatment options, thereby boosting both oral and injectable corticosteroid segments.

Oral (Dominant) vs. Injection (Emerging)

Oral corticosteroids are the dominant route of administration in the corticosteroids market due to attributes such as patient convenience, versatility in dosing, and broad accessibility. These corticosteroids are frequently prescribed for a range of conditions including autoimmune disorders and allergies, which contributes to their leading position in the market. On the other hand, injectable corticosteroids are emerging rapidly due to their targeted delivery and efficacy in acute situations. This method is particularly advantageous for conditions requiring immediate relief, such as severe asthma attacks or inflammatory flare-ups. The dual-market presence reflects the evolving treatment landscape, where patient-centric approaches and innovative therapies drive options between oral and injectable forms.

### By End Use: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Corticosteroids Market, the end use segment showcases diverse application areas, with hospitals holding the largest share due to their extensive patient volume and specialized treatment facilities. Hospitals are the primary setting for corticosteroid therapies, resulting in significant adoption that drives market stability. Meanwhile, clinics, which cater to outpatient services, are emerging rapidly, contributing to a shift in treatment dynamics and increasing their market presence significantly compared to traditional settings.

Hospitals: Dominant vs. Clinics: Emerging

Hospitals serve as the dominant force in the corticosteroids market, characterized by a wide array of services that include critical care, surgery, and outpatient consultation. Their ability to offer diverse treatment options and specialized care promotes a robust demand for corticosteroids. In contrast, clinics are viewed as an emerging segment, increasingly utilized for chronic disease management and preventive care. The rise of telemedicine and outpatient care models has led to a higher acceptance of corticosteroids within clinical practices, enhancing access to treatment and improving patient outcomes.

## Regional Market Share Analysis

The Corticosteroids Market shows significant regional variation, with North America leading the way. In 2024, North America is valued at 24.0 USD Billion, expected to rise to 30.0 USD Billion by 2035, highlighting its majority holding in the market due to advanced healthcare infrastructure and high demand for corticosteroid treatments. Europe follows as the second-largest market with a value of 15.5 USD Billion in 2024, increasing to 19.5 USD Billion in 2035, driven by the rising prevalence of autoimmune diseases. 

The APAC region, valued at 10.0 USD Billion in 2024 and projected to reach 12.5 USD Billion by 2035, is gaining traction as a growing market due to expanding healthcare facilities and increasing patient awareness.South America, with a market value of 4.2 USD Billion in 2024, is expected to grow to 5.2 USD Billion by 2035, presenting opportunities driven by enhancements in healthcare access. Meanwhile, the MEA region, though smaller at 4.0 USD Billion in 2024, is projected to increase to 5.8 USD Billion, showing potential as industries develop.

This regional segmentation reflects diverse market dynamics and varying growth drivers inherent in the Global Corticosteroids Market revenue landscape.

## Competitive Benchmarking

The Global Corticosteroids Market is characterized by a dynamic competitive landscape driven by various factors, including advancements in pharmaceutical technologies, increasing incidences of chronic diseases, and the growing acceptance of corticosteroid products in treating a wide range of health conditions such as autoimmune disorders, asthma, and allergies. The market includes a plethora of players ranging from established pharmaceutical giants to emerging biotech firms, each vying for market share through innovative drug formulations, strategic partnerships, and robust marketing strategies. 
Furthermore, regulatory approvals and clinical trial results heavily influence market dynamics, compelling companies to continuously invest in research and development to stay ahead in the competitive race. As the market evolves, trends such as personalized medicine and the development of combination therapies are expected to appear, creating new opportunities and challenges within the space.Roche holds a prominent position in the Global Corticosteroids Market due to its strong portfolio of products and commitment to innovation. The company leverages its extensive research capabilities to develop corticosteroid medications that address critical patient needs across multiple therapeutic areas.
Roche's strength lies in its established reputation for quality and efficacy, which enhances consumer trust and loyalty. 
Furthermore, strategic collaborations and partnerships allow Roche to enhance its market presence and expand its distribution channels. With a focus on patient-centric solutions, the company’s approach encompasses not only the pharmacological aspects of corticosteroids but also emphasizes education and support services for healthcare providers and patients alike. This holistic strategy positions Roche as a leader in the corticosteroid segment, ensuring both sustainability and growth in a competitive marketplace.Amgen, known primarily for its focus on innovative biologics, also plays a significant role in the Global Corticosteroids Market.
The company's integration of advanced biotechnological methods into corticosteroid production enhances the therapeutic impact and safety profiles of its offerings. 
Amgen’s commitment to research in chronic and inflammatory diseases positions it uniquely to capitalize on the increasing demand for effective corticosteroid treatments. The company has made substantial investments in clinical trials and RD initiatives to explore novel applications and formulations of corticosteroids, aligning its objectives with contemporary healthcare needs. In addition, Amgen's significant presence in emerging markets allows it to tap into new customer bases, thereby strengthening its competitive stance. By maintaining a focus on scientific innovation and leveraging its extensive experience in biologics, Amgen is positioned to redefine the landscape of the corticosteroid market in the years to come.

## Recent News & Developments

- **Q2 2024: FDA approves Hikma Pharmaceuticals’ generic version of Flovent HFA inhaler** Hikma Pharmaceuticals received FDA approval for its generic fluticasone propionate HFA inhalation aerosol, a corticosteroid used for asthma, marking a significant addition to the U.S. generic inhaler market.
- **Q1 2024: AstraZeneca receives EU approval for Airsupra, a fixed-dose combination including inhaled corticosteroid** AstraZeneca announced European Commission approval for Airsupra, a fixed-dose combination of albuterol and budesonide, expanding its respiratory portfolio in the corticosteroids segment.
- **Q2 2024: GSK launches Trelegy Ellipta in Japan for COPD and asthma** GlaxoSmithKline launched Trelegy Ellipta, a triple therapy inhaler containing an inhaled corticosteroid, in Japan following regulatory approval for use in both COPD and asthma patients.
- **Q1 2024: Sun Pharma receives US FDA approval for generic prednisolone oral solution** Sun Pharmaceutical Industries received US FDA approval to market its generic prednisolone oral solution, a corticosteroid used to treat various inflammatory and autoimmune conditions.
- **Q2 2024: Pfizer completes acquisition of Arena Pharmaceuticals, expanding immuno-inflammatory pipeline** Pfizer finalized its acquisition of Arena Pharmaceuticals, gaining access to a pipeline of immuno-inflammatory drugs, including corticosteroid-based therapies.
- **Q3 2024: Sanofi opens new manufacturing facility for corticosteroid inhalers in France** Sanofi inaugurated a new production facility in France dedicated to manufacturing inhaled corticosteroid products, aiming to meet growing European demand.
- **Q2 2024: Teva and Alvotech announce FDA acceptance of BLA for AVT04, a biosimilar to Stelara with corticosteroid-sparing potential** Teva and Alvotech reported that the FDA accepted their Biologics License Application for AVT04, a biosimilar to Stelara, which is used in combination with corticosteroids for certain autoimmune diseases.
- **Q1 2024: Novartis launches Enerzair Breezhaler in Canada, a triple therapy including inhaled corticosteroid** Novartis launched Enerzair Breezhaler, a triple combination inhaler containing an inhaled corticosteroid, in the Canadian market for asthma management.
- **Q2 2024: FDA approves Lupin’s generic budesonide inhalation suspension** Lupin received FDA approval for its generic budesonide inhalation suspension, a corticosteroid used in the treatment of asthma in pediatric patients.
- **Q3 2024: Cipla receives UK MHRA approval for Fluticasone Propionate nasal spray** Cipla received regulatory approval from the UK MHRA for its Fluticasone Propionate nasal spray, expanding its corticosteroid product offerings in Europe.
- **Q2 2024: Astellas Pharma announces partnership with Catalent for corticosteroid inhaler development** Astellas Pharma entered a partnership with Catalent to develop and manufacture a new inhaled corticosteroid therapy targeting respiratory diseases.
- **Q1 2025: Glenmark Pharmaceuticals receives US FDA approval for generic mometasone furoate nasal spray** Glenmark Pharmaceuticals received US FDA approval to market its generic mometasone furoate nasal spray, a corticosteroid indicated for allergic rhinitis.

## Report Scope

| MARKET SIZE 2024 | 57.7(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 59.09(USD Billion) |
| MARKET SIZE 2035 | 74.98(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 2.41% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer (US), Merck & Co. (US), Bristol-Myers Squibb (US), GlaxoSmithKline (GB), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Teva Pharmaceutical Industries (IL), Mylan (US) |
| Segments Covered | Types, Applications, Route of Administration, End Use, Regional |
| Key Market Opportunities | Advancements in targeted delivery systems enhance efficacy and reduce side effects in the Corticosteroids Market. |
| Key Market Dynamics | Rising demand for corticosteroids drives innovation and competition among pharmaceutical companies amid evolving regulatory landscapes. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Corticosteroids Market as of 2024?**
A: The Corticosteroids Market was valued at 57.7 USD Billion in 2024.

**Q: What is the projected market size for the Corticosteroids Market in 2035?**
A: The market is projected to reach 74.98 USD Billion by 2035.

**Q: What is the expected CAGR for the Corticosteroids Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Corticosteroids Market during 2025 - 2035 is 2.41%.

**Q: Which companies are considered key players in the Corticosteroids Market?**
A: Key players include Pfizer, Merck & Co., Bristol-Myers Squibb, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Teva Pharmaceutical Industries, and Mylan.

**Q: What are the main segments of the Corticosteroids Market by type?**
A: The main segments by type include Systemic Corticosteroids, Topical Corticosteroids, Inhaled Corticosteroids, Nasal Corticosteroids, and Ophthalmic Corticosteroids.

**Q: How much revenue is generated from Systemic Corticosteroids in 2024?**
A: Systemic Corticosteroids generated approximately 20.0 USD Billion in 2024.

**Q: What is the revenue forecast for Topical Corticosteroids by 2035?**
A: Topical Corticosteroids are projected to generate around 18.0 USD Billion by 2035.

**Q: Which application segment is expected to generate the highest revenue in 2035?**
A: Respiratory Disorders are expected to generate the highest revenue, projected at 18.0 USD Billion in 2035.

**Q: What is the revenue forecast for the Homecare segment by 2035?**
A: The Homecare segment is projected to reach approximately 12.0 USD Billion by 2035.

**Q: How does the revenue from Injection route of administration compare to Oral in 2035?**
A: In 2035, the revenue from the Injection route is projected at 15.0 USD Billion, while Oral is expected to reach 19.0 USD Billion.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/corticosteroids-market-43141*